ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas Share X ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation https://pharmaphorum.com/views-and-analysis/esmo-2022-paola-1-ovarian-cancer-and-treatment-innovation/
At ESMO 2022, oncologists saw exciting cancer advances Lung, breast, and non-prostate genitourinary (NGU) cancer treatments were the most exciting tracks due to the march towards Share X At ESMO 2022, oncologists saw exciting cancer advances https://pharmaphorum.com/views-and-analysis/at-esmo-2022-oncologists-saw-exciting-cancer-advances/
Bringing the promise of immunotherapy to a broader population When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their Share X Bringing the promise of immunotherapy to a broader population https://pharmaphorum.com/views-and-analysis/bringing-the-promise-of-immunotherapy-to-a-broader-population/
Reaching for the gold standard of lung cancer screening Time is a precious resource in oncology. Detecting patients with cancer as early as possible gives clinicians the Share X Reaching for the gold standard of lung cancer screening https://pharmaphorum.com/oncology/reaching-for-the-gold-standard-of-lung-cancer-screening/
Understanding the tumour micro-environment – the pharmaphorum podcast As our understanding of oncology has increased, it’s become clear that each cancer consists of much more than Share X Understanding the tumour micro-environment – the pharmaphorum podcast https://pharmaphorum.com/oncology/understanding-the-tumour-micro-environment/
How data is crucial to the relaunch of the Cancer Moonshot In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in Share X How data is crucial to the relaunch of the Cancer Moonshot https://pharmaphorum.com/views-and-analysis/how-data-is-crucial-to-the-relaunch-of-the-cancer-moonshot/
Low-Priced Oncology Disruptors: The Cuckoo in the PD-1/PD-L1 Nest or the Runt of the Clutch? Part I Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and Share X Low-Priced Oncology Disruptors: The Cuckoo in the PD-1/PD-L1 Nest or the Runt of the Clutch? https://pharmaphorum.com/views-and-analysis/low-priced-oncology-disruptors-the-cuckoo-in-the-pd-1-pd-l1-nest-or-the-runt/
Could vaccines soon be added to the ‘collective arsenal’ against cancer? The emergence of PD-(L1) treatments has provided patients options where previously none existed, and the leading forms of Share X Could vaccines soon be added to the ‘collective arsenal’ against cancer? https://pharmaphorum.com/views-and-analysis/could-vaccines-soon-be-added-to-the-collective-arsenal-against-cancer/
Are radiopharmaceuticals the next breakthrough in oncology? Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest Share X Are radiopharmaceuticals the next breakthrough in oncology? https://pharmaphorum.com/oncology/are-radiopharmaceuticals-the-next-breakthrough-in-oncology/
